MiR-145 blocked epithelial-mesenchymal transition of ovarian cancer cells by targeting FSCN1 [12], inhibited glutamine metabolism by targeting c-myc [14], inhibited the Warburg effect by targeting HK2 [16], and regulated RNA methylation by targeting YTHDF2 [24]. This evidence concerns the gene FSCN1 and ovarian cancer.